The evaluation in the efficacy of Radium-223 for overall survival among patients with mCRPC: A meta-analysis

Publications

Yen-Hsiang Chang1, Hao-Lun Luo2, Li-Yu Chen3, Shiang-Ling Lin3, Ya-Ting Huang3

1Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital, Taiwan
2Department of Urology, Kaohsiung Chang Gung Memorial Hospital, Taiwan
3Primo Biotechnology Co., Ltd, Taipei, Taiwan

This meta-analysis was presented at the 2024 Annual Meeting of the Taiwan Urological Association(2024 TUA).

Radium-223 is the first FDA-approved bone-targeting internal alpha particle-emitting radiotherapeutic agent and helps to delay symptomatic skeletal events and significantly improve quality of life.

Several studies have shown that radium-223 can effectively improve overall survival.

According to this meta-analysis, mCRPC patients who underwent 5-6 cycles of radium-223 treatment or combine it with androgen deprivation therapy (ADT) or chemotherapy (C/T) experienced improvements in overall survival. Although a significant difference in overall survival between radium-223 and placebo has not yet been observed, these analysis results still offer valuable insights for prostate cancer treatment.

About Primo

Primo collaborates with both domestic and international partners to accelerate progress in precision oncology, leveraging its capabilities in drug development, clinical translation, and GMP manufacturing to support next-generation therapeutics. For more information, please follow Primo Biotech on Facebook and LinkedIn.